BCG Unresponsive Disease A Roadmap for Drug Development and Integra;on of Novel Therapies

Size: px
Start display at page:

Download "BCG Unresponsive Disease A Roadmap for Drug Development and Integra;on of Novel Therapies"

Transcription

1 BCG Unresponsive Disease A Roadmap for Drug Development and Integra;on of Novel Therapies Seth P. Lerner, MD, FACS Professor of Urology Beth and Dave Swalm Chair in Urologic Oncology Baylor College of Medicine, Houston, Texas Future DirecEons in Urology August 19, 2017

2 Disclosures Clinical trials Endo, FKD, VivenEa NCI/SWOG Roche/Genentech, JBL Advisory Board BioCancell, Incyte, Nucleix, UroGen Consultant Biocancell, UroGen, Vaxiion 2

3 BCG Indica;ons Any paeent with high risk NMIBC TaHG, T1, Tis; mulefocal and recurrent and >3cm TaLG First occurrence standard of care Recurrent BCG naïve BCG failure (induceon) if no indicaeon for cystectomy or medically unfit FDA approved for CIS and high risk Ta,T1 3

4 Failure to Achieve a CR at 3 Months Status at 3 month cysto associated with outcome EORTC affirmed 3 years of maintenance BCG as standard of care for high risk NMIBC Lerner, et al Secondary analysis of SWOG 8507 Urologic Oncology 27:155,

5 Outcomes Following BCG Table 3 Multivariable analysis of disease-related variables and the associated risk of treatment failure in BCG failure patients with (A) any recurrent CIS or (B) recurrent pure papillary disease treated with intravesical BCG/IFN. (N denotes sample size) Note: # signifies that there was no significant difference between these two groups (A) Treatment Failure Level N HR 95% CI P-value Number of Prior BCG Courses 2 courses <.01 1 courses 55 Ref Prior BCG Failure Interval <6 Months <.01 # 6 12 Months >12 Months 28 Ref Total 98 (B) Treatment Failure Kaplan-Meier plot of treatment success of intravesical BCG/IFN in BCG Failure patients with recurrent CIS stratified by prior BCG failure interval and number of prior BCG failures including number at-risk. Images in this article Both prior BCG therapy and interval from last BCG are independently associated with recurrence probability Steinberg, et al Bladder Cancer 2:215,

6 Cystectomy is the Standard of Care for Pa;ents Who are Medically Fit 6

7 Cystectomy is the Standard of Care for Pa;ents Who are Medically Fit AUA 2016 In a high- risk paeent with persistent or recurrent disease within one year following treatment with two induceon cycles of BCG or BCG maintenance, a clinician should offer radical cystectomy. (Moderate RecommendaEon; Evidence Strength: Grade C) 7

8 Early vs. Delayed Cystectomy 105 pts, T1G3 with at least 2 risk factors CIS, large tumor, mulefocality) 51 refused cystectomy and treated with BCG. All ulemately had a delayed cystectomy (avg 11 months later) Cystectomy done at first sign of recurrence T1 or TIS or T2 (34%) Ø 5 yr CSS 83% vs. 67% Ganzinger Eur Urol 53:146,

9 Cystectomy in BCG Failure for CIS Long- term cancer control rates opemal with RC n=52 with CIS only at the ;me of RC All paeent underwent extended LND to IMA No paeent had lymph node metastasis 5- and 10- year RFS rates were 94% and 90%, Zahnder, et al BJU Int Jan

10 When BCG Fails the Pa;ent BCG/IFN for paeents treated with induceon only Valrubicin only FDA approved drug Gemcitabine OpEmized MMC Gem/MMC Gem/Docetaxel Clinical trial 10

11 Valrubicin 80 paeents with CIS 39% had at least 2 prior courses of BCG Received 6 or 9 weeks of Valrubicin 35% NED at 3 months THINK (posieve cytology allowed) CR at 6 months 18% 4% disease- free at 2 years Dinney et al Urol Onc 31:1635,2013

12 Gemcitabine SWOG S paeents all failed 2 courses BCG 89% high risk, 60% CIS 6 weekly treatments 2g in 100cc, then monthly x 12 Results: Ø 47% NED at 3 months Ø 28% conenuously disease- free at 12 mos Skinner J Urol 190:1200,

13 Gemcitabine/Docetaxel 45 paeents treated over 5 years InducEon only TaLG (4); TaHG (13) CIS (20); T1HG (8) 66% 54% 33% Steinberg, et al Bladder Cancer 1:65,

14 Device- assisted Chemotherapy Synergo microwave with MMC 1 51 paeents with CIS 34 failed prior BCG, 17 refractory (not reported separately) CR at 3 months 88% 22/45 (49%) recurred with median f/u 22 months 6 cystectomies ElectromoEve MMC (EMDA) promising US trials in BCG- recurrent paeents in planning phase 1 Witjes et al World J Urol 2009;27:319 14

15 Bladder Cancer Drug Development Valrubicin approved in 1998 BCG refractory CIS in paeents who refuse or are medically unfit for cystectomy No new drugs approved unel May 2016 Atezolizumab Now 5 immunotherapy agents targeeng PD1- PD- L1 gained accelerated or condieonal approval in metastaec disease plaenum refractory or plaenum ineligible

16 Bladder Cancer Drug Development Must have a drug approval process that is transparent and achievable Challenges: Therapy vs. adjuvant Mixed disease stage Ta/T1 and CIS. Adjuvant requires a control arm in order to power for treatment effect Unethical to have a no treatment control arm and only the approved drug does not have a favorable enough treatment effect

17 FDA/AUA/SUO Guidance Urology 83:262, /30/ /26/2015 SUO- CTC sponsored joint meeeng with CDER and CBER at FDA 4/18/

18 BCG Unresponsive high risk NMIBC Recurrent/persistent high grade urothelial carcinoma aoer compleeon of at least induceon and one cycle maintenance BCG ( 5+2 ) for high grade Ta/T1 or CIS Never achieved CR or recurred within 6 months of last BCG dose T1HG at first evaluaeon aoer induceon BCG at least 5 of 6 induceon doses These paeents are extremely unlikely to respond to further BCG Lerner et al, Bladder Cancer 1:29, 2015)

19 DraW FDA Guidance November

20 Clinical Trial Design FDA Guidance Randomizing paeents with BCG- unresponsive disease to a minimally effeceve drug as a concurrent control raises ethical concerns. Because effeceve drugs are not available and the alternaeve treatment is cystectomy, single- arm trials of paeents with BCG unresponsive CIS disease with or without papillary disease are appropriate. Primary endpoint should be complete response in paeents with CIS 20

21 Clinical Trials Ad- IFN gene therapy (FKD) SUO- CTC Viccinium (VivenEa) Atezolizumab (SWOG S Roche/GNE) Pembrolizumab (Merck) Nab- Rapamycin- ABI- 009 Phase I/II (AADi LLC) Cabazitaxel, gemcitabine, and cisplaen Phase I (Columbia) BGJ 398 FGFR targeted therapy (MSKCC) ChemoXRT for T1 (RTOG 0926) 21

22 Ad- IFN (FKD/SUOCTC) A Phase III, Open Label Study to Evaluate the Safety and Efficacy of INSTILADRIN (rad- IFN/ Syn3) Administered Intravesically to PaEents with High Grade, BCG Unresponsive, NMIBC PI - Boorjian Primary aim: To evaluate the incidence of HG Event- Free Survival at 12 months Treatment: Ad/IFN 3 x 1011 vp/ml135 paeents; 35 responding paeents at 12 months (RR 25.2%, 95% CI = [18.1%, 33.4%])

23 Ad- IFN (FKD/SUOCTC) Intravesical dosing at 3 month intervals x 4; mos 1,4,7,10 Responding paeents may conenue treatment year 2

24 S1605: Phase 2 trial of Atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer. (PI Peter Black) Rationale: High risk NMIBC responds to immunotherapy PDL1 is expressed in NMIBC 1 Encouraging results in metastatic disease 2,3 Hypothesis: checkpoint molecules facilitate immune evasion in BCG-unresponsive NMIBC and this can be overcome with checkpoint inhibitors 1 Inman et al, Cancer Powles et al, Nature Rosenberg, Lancet 2016

25 Study Scheme BCG unresponsive Ta/T1/Tis (TURBT) Atezolizumab Atezolizumab Atezolizumab q 3 weeks Atezolizumab registration within 6 weeks of TURBT start therapy within 5 days of registration Atezolizumab cysto cytol Atezolizumab Atezolizumab Atezolizumab 13 wks* q 3 weeks Atezolizumab cysto biopsy cytol Atezolizumab maintenance q3wks for 9 cycles 25 weeks* (=6 months post TURBT) surveillance for 18 mo. 18 months * time is relative to first dose of atezolizumab

26 Co-Primary Endpoints 1. Complete response (CR) in patients with CIS negative cytology, cystoscopy, biopsy at 6 months (n = 70) if 28 (40%) or more patients respond, the agent would be considered promising 2. Event-free survival (EFS) at 18 months for overall study cohort recurrence = any high grade tumor or any metastasis

27 Take Home Message BCG Unresponsive state is unlikely to respond to addieonal BCG ± IFN and is associated with increased risk for progression to muscle invasive disease Radical cystectomy has a high probability of long term cancer control and is standard of care per current Guidelines 27

28 Take Home Message FDA in collaboraeon with muleple stakeholders has defined a registraeon pathway via a single arm trial design with efficacy determined by inieal and durable CR for CIS Intravesical therapy and clinical trials of new agents are appropriate for those paeents who do not need immediate cystectomy, refuse or are medically unfit for cystectomy 28

BC G Unresponsive Non- Muscle Invasive Bladder Cancer

BC G Unresponsive Non- Muscle Invasive Bladder Cancer BC G Unresponsive Non- Muscle Invasive Bladder Cancer Seth P. Lerner, MD, FACS Professor of Urology Beth and Dave Swalm Chair in Urologic Oncology ScoA Department of Urology Baylor College of Medicine,

More information

BCG Unresponsive NMIBC: What s Available?

BCG Unresponsive NMIBC: What s Available? BCG Unresponsive NMIBC: What s Available? Michael S. Cookson, MD, MMHC, FACS Professor and Chair Department of Urology University of Oklahoma TwiLer @uromc Professional Practice Gap Gap 1: There is incomplete

More information

Management of High-Risk Non-Muscle Invasive Bladder Cancer. Seth P. Lerner, MD, FACS

Management of High-Risk Non-Muscle Invasive Bladder Cancer. Seth P. Lerner, MD, FACS Management of High-Risk Non-Muscle Invasive Bladder Cancer Seth P. Lerner, MD, FACS Professor of Urology, Beth and Dave Swalm Chair in Urologic Oncology, Scott Department of Urology, Baylor College of

More information

Novel therapeutic strategies for NMIBC. Peter Black Vancouver Prostate Centre University of British Columbia

Novel therapeutic strategies for NMIBC. Peter Black Vancouver Prostate Centre University of British Columbia Novel therapeutic strategies for NMIBC Peter Black Vancouver Prostate Centre University of British Columbia Financial and Other Disclosures I have the following financial interests or relationships to

More information

Management options for high-risk, BCG-refractory NMIBC. Alan M. Nieder, M.D. Columbia University Division of Urology Mount Sinai Medical Center

Management options for high-risk, BCG-refractory NMIBC. Alan M. Nieder, M.D. Columbia University Division of Urology Mount Sinai Medical Center Management options for high-risk, BCG-refractory NMIBC Alan M. Nieder, M.D. Columbia University Division of Urology Mount Sinai Medical Center Bladder Cancer in U.S. 4 th most common cancer in men 9 th

More information

The Rationale for Immunotherapy as an Adjuvant Treatment for Locally Advanced BC

The Rationale for Immunotherapy as an Adjuvant Treatment for Locally Advanced BC The Rationale for Immunotherapy as an Adjuvant Treatment for Locally Advanced BC Seth P. Lerner, MD, FACS Professor, Scott Department of Urology Beth and Dave Swalm Chair in Urologic Oncology Baylor College

More information

Reviewing Immunotherapy for Bladder Carcinoma In Situ

Reviewing Immunotherapy for Bladder Carcinoma In Situ Reviewing Immunotherapy for Bladder Carcinoma In Situ Samir Bidnur Dept of Urologic Sciences, Grand Rounds March 1 st, 2017 Checkpoint Inhibition and Bladder Cancer, an evolving story with immunotherapy

More information

Non-Muscle Invasive Bladder Cancer BCG Failures: University of Iowa Hospitals and Clinics Experience. Paul Gellhaus Assistant Clinical Professor

Non-Muscle Invasive Bladder Cancer BCG Failures: University of Iowa Hospitals and Clinics Experience. Paul Gellhaus Assistant Clinical Professor Non-Muscle Invasive Bladder Cancer BCG Failures: University of Iowa Hospitals and Clinics Experience Paul Gellhaus Assistant Clinical Professor Iowa??? none Disclosures Caveats Dr. Michael O Donnell

More information

Should the primary be treated in patients with metastatic disease? Upper Tract Urothelial Cancer

Should the primary be treated in patients with metastatic disease? Upper Tract Urothelial Cancer Should the primary be treated in patients with metastatic disease? Upper Tract Urothelial Cancer Seth P. Lerner, MD, FACS Professor, Scott Department of Urology Beth and Dave Swalm Chair in Urologic Oncology

More information

Lymphadenectomy in Invasive Bladder Cancer: Knowns and Unknowns Seth P. Lerner, MD, FACS Professor of Urology Beth and Dave Swalm Chair in Urologic

Lymphadenectomy in Invasive Bladder Cancer: Knowns and Unknowns Seth P. Lerner, MD, FACS Professor of Urology Beth and Dave Swalm Chair in Urologic Lymphadenectomy in Invasive Bladder Cancer: Knowns and Unknowns Seth P. Lerner, MD, FACS Professor of Urology Beth and Dave Swalm Chair in Urologic Oncology Scott Department of Urology Baylor College of

More information

Intravesical Therapy for Bladder Cancer

Intravesical Therapy for Bladder Cancer Intravesical Therapy for Bladder Cancer Alexandre R. Zlotta, MD, PhD, FRCSC Professor, Department of Surgery (Urology), University of Toronto Director, Uro-Oncology, Mount Sinai Hospital Director, Uro-Oncology

More information

Non Muscle Invasive Bladder Cancer. Primary and Recurrent TCC 4/10/2010. Two major consequences: Strategies: High-Risk NMI TCC

Non Muscle Invasive Bladder Cancer. Primary and Recurrent TCC 4/10/2010. Two major consequences: Strategies: High-Risk NMI TCC Intravesical Therapy 2010-When, with What, When to Stop Friday, April 9, 2010 Ralph de VereWhite, MD Director, UC Davis Cancer Center Associate Dean for Cancer Programs Professor, Department of Urolgoy

More information

Risk Adapted Treatment of Non-muscle Invasive Bladder Cancer. Eila C. Skinner, MD

Risk Adapted Treatment of Non-muscle Invasive Bladder Cancer. Eila C. Skinner, MD Risk Adapted Treatment of Non-muscle Invasive Bladder Cancer Eila C. Skinner, MD Professor, Department of Urology Stanford University SWIU Winter Meeting January, 2015 Goals Minimize treatment for patients

More information

Management of High Grade, T1 Bladder Cancer Douglas S. Scherr, M.D.

Management of High Grade, T1 Bladder Cancer Douglas S. Scherr, M.D. Management of High Grade, T1 Bladder Cancer Douglas S. Scherr, M.D. Assistant Professor of Urology Clinical Director, Urologic Oncology Weill Medical College-Cornell University Estimated new cancer cases.

More information

BCG Failure or BCG Unresponsive: Defining and Managing Difficult Patients

BCG Failure or BCG Unresponsive: Defining and Managing Difficult Patients BCG Failure or BCG Unresponsive: Defining and Managing Difficult Patients Michael S. Cookson, MD, Professor and Chair Department of Urology University of Oklahoma Non-muscle Invasive Bladder Cancer Bladder

More information

Current Experience with Intrapelvic/Intraureteral Irrigation/Ablative Therapy

Current Experience with Intrapelvic/Intraureteral Irrigation/Ablative Therapy Current Experience with Intrapelvic/Intraureteral Irrigation/Ablative Therapy Seth P. Lerner, MD, FACS Beth and Dave Swalm Chair in Urologic Oncology Scott Department of Urology Baylor College of Medicine

More information

Optimising the management of non-muscle invasive bladder cancer from diagnosis to cure. Dr Richard Savdie Uro-Oncology Fellow BSc MBBS FRACS

Optimising the management of non-muscle invasive bladder cancer from diagnosis to cure. Dr Richard Savdie Uro-Oncology Fellow BSc MBBS FRACS Optimising the management of non-muscle invasive bladder cancer from diagnosis to cure Dr Richard Savdie Uro-Oncology Fellow BSc MBBS FRACS Objectives 1. Explore best practice diagnostic techniques 2.

More information

Controversies in the management of Non-muscle invasive bladder cancer

Controversies in the management of Non-muscle invasive bladder cancer Controversies in the management of Non-muscle invasive bladder cancer Sia Daneshmand, MD Associate Professor of Urology (Clinical Scholar) Director of Urologic Oncology Director of Clinical Research Urologic

More information

Disclosures. The Importance of Pathology? Pathologic, Morphologic and Clinical Features. Pathologic Reproducibility

Disclosures. The Importance of Pathology? Pathologic, Morphologic and Clinical Features. Pathologic Reproducibility The Importance of Pathology? Seth P. Lerner, MD, FACS Beth and Dave Swalm Chair in Urologic Oncology Scott Department of Urology Baylor College of Medicine Support for research Disclosures Photocure, Imalux,

More information

Options for first-line cisplatin-eligible patients

Options for first-line cisplatin-eligible patients The Past Options for first-line cisplatin-eligible patients Metastatic urothelial cancer Cisplatin-eligible Gemcitabine/ cisplatin MVAC or high-dose intensity MVAC Paclitaxel/ cisplatin/ gemcitabine Bellmunt

More information

Issues in the Management of High Risk Superficial Bladder Cancer

Issues in the Management of High Risk Superficial Bladder Cancer Issues in the Management of High Risk Superficial Bladder Cancer MICHAEL A.S. JEWETT DIVISION OF UROLOGY, DEPARTMENT OF SURGICAL ONCOLOGY, PRINCESS MARGARET HOSPITAL & THE UNIVERSITY OF TORONTO 1 Carcinoma

More information

IMMUNE CHECKPOINT THERAPY FOR GENITOURINARY CANCERS: KIDNEY CANCER AND TRANSITIONAL CELL CARCINOMA

IMMUNE CHECKPOINT THERAPY FOR GENITOURINARY CANCERS: KIDNEY CANCER AND TRANSITIONAL CELL CARCINOMA IMMUNE CHECKPOINT THERAPY FOR GENITOURINARY CANCERS: KIDNEY CANCER AND TRANSITIONAL CELL CARCINOMA Kathleen Mahoney, M.D., Ph.D. Instructor of Medicine, Harvard Medical School Attending, Beth Israel Deaconess

More information

Urinary Bladder Cancer

Urinary Bladder Cancer Fellow GU Lecture Series, 2018 Urinary Bladder Cancer Asit Paul, MD, PhD 01/31/2018 Overview Non-muscle invasive bladder cancer Muscle invasive bladder cancer Bladder sparing chemo-radiation therapy T4b

More information

Neoadjuvant vs. Adjuvant Chemotherapy for Muscle-Invasive Bladder Cancer

Neoadjuvant vs. Adjuvant Chemotherapy for Muscle-Invasive Bladder Cancer Neoadjuvant vs. Adjuvant Chemotherapy for Muscle-Invasive Bladder Cancer Andrew J. Stephenson, MD, FRCSC, FACS Director, Urologic Oncology Associate Professor of Surgery Glickman Urological and Kidney

More information

Intravesical Gemcitabine for High Risk, Nonmuscle Invasive Bladder Cancer after Bacillus Calmette-Guerin Treatment Failure

Intravesical Gemcitabine for High Risk, Nonmuscle Invasive Bladder Cancer after Bacillus Calmette-Guerin Treatment Failure Intravesical Gemcitabine for High Risk, Nonmuscle Invasive Bladder Cancer after Bacillus Calmette-Guerin Treatment Failure Itay A. Sternberg, Guido Dalbagni,* Ling Y. Chen, Sherri M. Donat, Bernard H.

More information

When to Integrate Surgery for Metatstatic Urothelial Cancers

When to Integrate Surgery for Metatstatic Urothelial Cancers When to Integrate Surgery for Metatstatic Urothelial Cancers Wade J. Sexton, M.D. Senior Member and Professor Department of Genitourinary Oncology Moffitt Cancer Center Case Presentation #1 67 yo male

More information

RITE Thermochemotherapy in the treatment of BCG refractory NMIBC

RITE Thermochemotherapy in the treatment of BCG refractory NMIBC RITE Thermochemotherapy in the treatment of BCG refractory NMIBC Ben Ayres Consultant Urological Surgeon St George s Hospital London 1 Financial and Other Disclosures Off-label use of drugs, devices, or

More information

Management of Superficial Bladder Cancer Douglas S. Scherr, M.D.

Management of Superficial Bladder Cancer Douglas S. Scherr, M.D. Management of Superficial Bladder Cancer Douglas S. Scherr, M.D. Assistant Professor of Urology Clinical Director, Urologic Oncology Weill Medical College-Cornell University Estimated new cancer cases.

More information

TARGETING CANCER WITH POWER AND PRECISION

TARGETING CANCER WITH POWER AND PRECISION TARGETING CANCER WITH POWER AND PRECISION T h o m a s C a n n e l l, D. V. M., P r e s i d e n t a n d C E O A u g u s t 9, 2 0 1 8 NASDAQ: SESN FORWARD-LOOKING STATEMENTS This presentation contains forward-looking

More information

Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer

Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer Patrick A. Cockerill, John J. Knoedler, Igor Frank, Robert Tarrell and Robert

More information

Treatment of Invasive Bladder Cancer in the Elderly and Frail Pa9ent

Treatment of Invasive Bladder Cancer in the Elderly and Frail Pa9ent Treatment of Invasive Bladder Cancer in the Elderly and Frail Pa9ent Jehonathan H Pinthus MD, Ph.D, FRCSC Associate Professor Department of Surgery/Urology McMaster University Life expectancy Current age

More information

Sequential Intravesical Gemcitabine and Docetaxel for the Salvage Treatment of Non-Muscle Invasive Bladder Cancer

Sequential Intravesical Gemcitabine and Docetaxel for the Salvage Treatment of Non-Muscle Invasive Bladder Cancer Bladder Cancer 1 (2015) 65 72 DOI 10.3233/BLC-150008 IOS Press Research Report 65 Sequential Intravesical Gemcitabine and Docetaxel for the Salvage Treatment of Non-Muscle Invasive Bladder Cancer Ryan

More information

T1HG Bladder Cancer What is the Best Therapy?

T1HG Bladder Cancer What is the Best Therapy? T1HG Bladder Cancer What is the Best Therapy? Ashish M. Kamat, MD, MBBS, FACS Professor of Urology Director, Urologic Oncology Fellowship Guidelines for T1HG Bladder Cancer AUA Recommendation: BCG induction

More information

Collection of Recorded Radiotherapy Seminars

Collection of Recorded Radiotherapy Seminars IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org Conservative Treatment of Invasive Bladder Cancer Luis Souhami, MD Professor Department of Radiation Oncology

More information

Oral Communications & Posters

Oral Communications & Posters Carcinoma uroteliale: Current and future directions of treatment of Muscle-Invasive Bladder cancer/ Multimodality approach of bladder cancer Oral Communications & Posters CRISTINA MASINI Oncologia Medica

More information

Research Report. Keywords: Bladder Cancer, BCG failure, virtual clinical trial, mitomycin C

Research Report. Keywords: Bladder Cancer, BCG failure, virtual clinical trial, mitomycin C Bladder Cancer 1 (2015) 143 150 DOI 10.3233/BLC-150020 IOS Press Research Report 143 Novel Simulation Model of Non-Muscle Invasive Bladder Cancer: A Platform for a Virtual Randomized Trial of Conservative

More information

Lymphadenectomy in RCC: Yes, No, Clinical Trial?

Lymphadenectomy in RCC: Yes, No, Clinical Trial? Lymphadenectomy in RCC: Yes, No, Clinical Trial? Viraj Master MD PhD FACS Professor Associate Chair for Clinical Affairs and Quality Director of Clinical Research Unit Department of Urology Emory University

More information

Urothelial Cancers- New Strategies. Sandy Srinivas.MD Stanford University

Urothelial Cancers- New Strategies. Sandy Srinivas.MD Stanford University Urothelial Cancers- New Strategies Sandy Srinivas.MD Stanford University Relevant financial relationships in the past twelve months by presenter or spouse/partner. Consultant: Genentech, Astra Zeneca The

More information

Updates in Immunotherapy for Urothelial Carcinoma

Updates in Immunotherapy for Urothelial Carcinoma Updates in Immunotherapy for Urothelial Carcinoma Andrew J Armstrong MD ScM FACP DUA 2018 Copyright 2006 SciMed. Talk Outline Immunotherapy progress in 2017: 5 new approved PD-1/PD-L1 inhibitory agents

More information

Bacille-Calmette-Guerin non-responders: how to manage

Bacille-Calmette-Guerin non-responders: how to manage Review Article Bacille-Calmette-Guerin non-responders: how to manage Friedrich-Carl von Rundstedt 1,2, Seth P. Lerner 1 1 Scott of Department of Urology, Translational Biology and Molecular Medicine, Dan

More information

GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER

GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER (Limited text update December 21) M. Babjuk, W. Oosterlinck, R. Sylvester, E. Kaasinen, A. Böhle, J. Palou, M. Rouprêt Eur Urol 211 Apr;59(4):584-94 Introduction

More information

Critical Evaluation of Early Post-operative Single Instillation Therapy in NMIBC

Critical Evaluation of Early Post-operative Single Instillation Therapy in NMIBC Critical Evaluation of Early Post-operative Single Instillation Therapy in NMIBC Levent N. Türkeri MD, PhD Professor of Urology Acıbadem University Faculty of Medicine Istanbul Conflict of Interest No

More information

Old and New Radiation for Bladder and Upper Tract Cancers. Bridget Koontz Radiation Oncology Duke Cancer Institute

Old and New Radiation for Bladder and Upper Tract Cancers. Bridget Koontz Radiation Oncology Duke Cancer Institute Old and New Radiation for Bladder and Upper Tract Cancers Bridget Koontz Radiation Oncology Duke Cancer Institute Disclosures Janssen funded clinical research BlueEarth Diagnostics advisory board member

More information

Contemporary management of high-grade T1 bladder cancer Arnulf Stenzl

Contemporary management of high-grade T1 bladder cancer Arnulf Stenzl Contemporary management of high-grade T1 bladder cancer Arnulf Stenzl Dep. of Urology, Eberhard-Karls University, Tuebingen, Germany Treatment options in HG T1 BCa TUR-BT Primary and second resection (T0-status)

More information

Paul F. Schellhammer, M.D. Eastern Virginia Medical School Urology of Virginia Norfolk, Virginia

Paul F. Schellhammer, M.D. Eastern Virginia Medical School Urology of Virginia Norfolk, Virginia Paul F. Schellhammer, M.D. Eastern Virginia Medical School Urology of Virginia Norfolk, Virginia Virginia - Chesapeake Bay Landfall: Virginia Beach, April 29 th, 1607 PSA Failure after Radical Prostatectomy

More information

The Impact of Blue Light Cystoscopy with Hexaminolevulinate (HAL) on Progression of Bladder Cancer ANewAnalysis

The Impact of Blue Light Cystoscopy with Hexaminolevulinate (HAL) on Progression of Bladder Cancer ANewAnalysis Bladder Cancer 2 (2016) 273 278 DOI 10.3233/BLC-160048 IOS Press Research Report 273 The Impact of Blue Light Cystoscopy with Hexaminolevulinate (HAL) on Progression of Bladder Cancer ANewAnalysis Ashish

More information

A Personal History NIH CWRU U of TN U of Miami Animal Model for Bladder Cancer Carcinogen induced FANFT Three Models Primary tumors individual tumors, simulates clinical scenario of locally advanced cancer

More information

UROTHELIAL CELL CANCER

UROTHELIAL CELL CANCER UROTHELIAL CELL CANCER Indications and regimens for neoadjuvant systemic treatment Astrid A. M. van der Veldt, MD, PhD, medical oncologist Department of Medical Oncology Erasmus Medical Center Cancer Institute

More information

Veterans and Bladder Cancer webinar. Part I: Medical Overview

Veterans and Bladder Cancer webinar. Part I: Medical Overview Veterans and Bladder Cancer webinar Tuesday March 1, 2016 Part I: Medical Overview Presented by Dr. Jennifer Taylor is an assistant professor of urology at the University of Pittsburgh School of Medicine.

More information

Should We Screen for Bladder Cancer in a High Risk Population: A Cost per Life-Year Saved Analysis?

Should We Screen for Bladder Cancer in a High Risk Population: A Cost per Life-Year Saved Analysis? Should We Screen for Bladder Cancer in a High Risk Population: A Cost per Life-Year Saved Analysis? Yair Lotan, Robert S. Svatek, Arthur I. Sagalowsky Should We Screen? Prevalence 5 th most common cancer

More information

Predicting Response to Intravesical Immunotherapy (BCG) in NMIBC

Predicting Response to Intravesical Immunotherapy (BCG) in NMIBC Predicting Response to Intravesical Immunotherapy (BCG) in NMIBC Ashish M. Kamat, MD, MBBS, FACS Professor of Urologic Oncology Wayne B. Duddlesten Professor of Cancer Research President, International

More information

Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma

Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma Kamat et al. Journal for ImmunoTherapy of Cancer (2017) 5:68 DOI 10.1186/s40425-017-0271-0 POSITION ARTICLE AND GUIDELINES Society for Immunotherapy of Cancer consensus statement on immunotherapy for the

More information

Clinical significance of immediate urine cytology after transurethral resection of bladder tumor in patients with non-muscle invasive bladder cancer

Clinical significance of immediate urine cytology after transurethral resection of bladder tumor in patients with non-muscle invasive bladder cancer International Journal of Urology (2011) 18, 439 443 doi: 10.1111/j.1442-2042.2011.02766.x Original Article: Clinical Investigationiju_2766 439..443 Clinical significance of immediate urine cytology after

More information

Bladder Cancer: Long-Term Survival With Metastatic Disease Case Reports and Review of the Literature. William Julian, MD. James J.

Bladder Cancer: Long-Term Survival With Metastatic Disease Case Reports and Review of the Literature. William Julian, MD. James J. Bladder Cancer: Long-Term Survival With Metastatic Disease Case Reports and Review of the Literature William Julian, MD James J. Stark, MD, FACP Maryview Medical Center February 20, 2009 Dr. Julian to

More information

Urine Markers for Bladder Cancer. Peter Black, MD, FACS, FRCSC Khosrowshahi Family Chair Vancouver Prostate Centre University of British Columbia

Urine Markers for Bladder Cancer. Peter Black, MD, FACS, FRCSC Khosrowshahi Family Chair Vancouver Prostate Centre University of British Columbia Urine Markers for Bladder Cancer Peter Black, MD, FACS, FRCSC Khosrowshahi Family Chair Vancouver Prostate Centre University of British Columbia Disclosures Role Consultant/Speaker Grant Funding Clinical

More information

September 10, Dear Dr. Clark,

September 10, Dear Dr. Clark, September 10, 2015 Peter E. Clark, MD Chair, NCCN Bladder Cancer Guidelines (Version 2.2015) Associate Professor of Urologic Surgery Vanderbilt Ingram Cancer Center Nashville, TN 37232 Dear Dr. Clark,

More information

Lymph node dissection: how much is enough?

Lymph node dissection: how much is enough? 1 Background Lymph node dissection: how much is enough? Eila C. Skinner, MD Professor of Clinical Urology USC Keck School of Medicine Radical cystectomy is the gold standard for the treatment of invasive

More information

Updated Phase 3 VISTA Trial Data in Patients with BCG-unresponsive Non-muscle Invasive Bladder Cancer. January 4, 2019 NASDAQ SESN

Updated Phase 3 VISTA Trial Data in Patients with BCG-unresponsive Non-muscle Invasive Bladder Cancer. January 4, 2019 NASDAQ SESN Updated Phase 3 VISTA Trial Data in Patients with BCG-unresponsive Non-muscle Invasive Bladder Cancer January 4, 2019 NASDAQ SESN FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements

More information

Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer

Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Jimmy Ruiz, MD Assistant Professor Thoracic Oncology Program Wake Forest Comprehensive Cancer Center Disclosures I have no actual

More information

THE SEARCH FOR BIOMARKERS IN BLADDER CANCER

THE SEARCH FOR BIOMARKERS IN BLADDER CANCER THE SEARCH FOR BIOMARKERS IN BLADDER CANCER CDDP and IO WORLD ALEJO RODRÍGUEZ-VIDA MD PhD Consultant Medical Oncologist Associate Professor Hospital del Mar, Barcelona November 23 rd 2018 DISCLOSURE OF

More information

RCC in Adolescents and Young Adults (AYAs): Diagnosis and Management

RCC in Adolescents and Young Adults (AYAs): Diagnosis and Management RCC in Adolescents and Young Adults (AYAs): Diagnosis and Management Nicholas G. Cost, M.D. Assistant Professor, Department of Surgery, Division of Urology University of Colorado Cancer Center Fifteenth

More information

A Giant Leap in the Treatment Options for Advanced Bladder Cancer

A Giant Leap in the Treatment Options for Advanced Bladder Cancer A Giant Leap in the Treatment Options for Advanced Bladder Cancer Yohann Loriot, MD, PhD Department of Cancer Medicine & INSERM U981 Gustave Roussy Villejuif, France Clinical Features of Bladder Cancer

More information

Business Update. March 4, 2019 NASDAQ SESN

Business Update. March 4, 2019 NASDAQ SESN Business Update March 4, 2019 NASDAQ SESN FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements

More information

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of intravesical microwave hyperthermia with intravesical chemotherapy for superficial

More information

Some Seminal Studies. Chemotherapy Alone is Inadequate. Bladder Cancer Role of Radiation in Bladder Sparing. Primary Radiation for Bladder Cancer

Some Seminal Studies. Chemotherapy Alone is Inadequate. Bladder Cancer Role of Radiation in Bladder Sparing. Primary Radiation for Bladder Cancer Bladder Cancer Role of Radiation in Bladder Sparing David C. Beyer M.D., FACR, FACRO, FASTRO Arizona Oncology Services Phoenix, Arizona Primary Radiation for Bladder Cancer No modern surgery / XRT randomized

More information

Chemotherapy and Bladder Cancer. Blayne Welk UBC Urology Grand Rounds June 4, 2008

Chemotherapy and Bladder Cancer. Blayne Welk UBC Urology Grand Rounds June 4, 2008 Chemotherapy and Bladder Cancer Blayne Welk UBC Urology Grand Rounds June 4, 2008 Outline Review of Incidence and Impact of bladder cancer Neoadjuvant chemotherapy Adjuvant chemotherapy Bladder preservation

More information

CUA guidelines on the management of non-muscle invasive bladder cancer

CUA guidelines on the management of non-muscle invasive bladder cancer Original cua guidelines research CUA guidelines on the management of non-muscle invasive bladder cancer Wassim Kassouf, MD, CM, FRCSC; * Samer L. Traboulsi, MD; * Girish S. Kulkarni, MD, FRCSC; Rodney

More information

The Clinical Impact of the Classification of Carcinoma In Situ on Tumor Recurrence and their Clinical Course in Patients with Bladder Tumor

The Clinical Impact of the Classification of Carcinoma In Situ on Tumor Recurrence and their Clinical Course in Patients with Bladder Tumor Original Article Japanese Journal of Clinical Oncology Advance Access published December 17, 2010 Jpn J Clin Oncol 2010 doi:10.1093/jjco/hyq228 The Clinical Impact of the Classification of Carcinoma In

More information

Discovery and Validation of Prognostic Genomic Based Signatures in High Risk Bladder Cancer Following Cystectomy

Discovery and Validation of Prognostic Genomic Based Signatures in High Risk Bladder Cancer Following Cystectomy Discovery and Validation of Prognostic Genomic Based Signatures in High Risk Bladder Cancer Following Cystectomy Anirban P. Mitra, M.D., Ph.D. Center for Personalized Medicine University of Southern California

More information

Case 1. Receives induction BCG weekly x 6 without significant toxicity Next step should be:

Case 1. Receives induction BCG weekly x 6 without significant toxicity Next step should be: Case 1 89 year old male with initial occurrence of gross hematuria Office flexible cystoscopy shows two papillary tumors with some surface necrosis Complete TURBT into muscle Florescence cysto shows two

More information

Alicia K. Morgans, MD Assistant Professor of Medicine Division of Hematology/Oncology Vanderbilt University Medical Center January 24, 2015

Alicia K. Morgans, MD Assistant Professor of Medicine Division of Hematology/Oncology Vanderbilt University Medical Center January 24, 2015 Alicia K. Morgans, MD Assistant Professor of Medicine Division of Hematology/Oncology Vanderbilt University Medical Center January 24, 2015 Overview Background Perioperative chemotherapy in MIBC Neoadjuvant

More information

UC San Francisco UC San Francisco Previously Published Works

UC San Francisco UC San Francisco Previously Published Works UC San Francisco UC San Francisco Previously Published Works Title Multi-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non-muscle invasive bladder cancer

More information

ROBOTIC VS OPEN RADICAL CYSTECTOMY

ROBOTIC VS OPEN RADICAL CYSTECTOMY ROBOTIC VS OPEN RADICAL CYSTECTOMY A REVIEW Colin Lundeen December 14, 2016 Objectives Review the history of radical cystectomy Critically analyze recent RCTs comparing open radical cystectomy (ORC) to

More information

THE USE OF HALF DOSE BCG FOR INTRAVESICAL IMMUNOTHERAPY IN NON MUSCLE INVASIVE BLADDER CANCER

THE USE OF HALF DOSE BCG FOR INTRAVESICAL IMMUNOTHERAPY IN NON MUSCLE INVASIVE BLADDER CANCER THE USE OF HALF DOSE BCG FOR INTRAVESICAL IMMUNOTHERAPY IN NON MUSCLE INVASIVE BLADDER CANCER Mihály Zoltán Attila 1, Rusu Cristian Bogdan 2, Mihály Orsolya Maria 3, Bolboacă Sorana Daniela 4, Bungărdean

More information

Early radical cystectomy in NMIBC Marko Babjuk

Early radical cystectomy in NMIBC Marko Babjuk Early radical cystectomy in NMIBC Marko Babjuk Dept. of Urology, 2nd Faculty of Medicine, Hospital Motol, Praha, Czech Republic We Are The European Association of Urology We Are Urologists, residents,

More information

Challenges in systemic treatment for metastatic bladder cancer. Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University

Challenges in systemic treatment for metastatic bladder cancer. Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University Challenges in systemic treatment for metastatic bladder cancer Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University OS PCG 15.8 vs GC 12.7 NS Cisplatin ineligible Second-line chemotherapy

More information

Maintenance Therapy with Intravesical Bacillus Calmette Guérin in Patients with Intermediate- or High-risk Non-muscle-invasive

Maintenance Therapy with Intravesical Bacillus Calmette Guérin in Patients with Intermediate- or High-risk Non-muscle-invasive Jpn J Clin Oncol 2013;43(3)305 313 doi:10.1093/jjco/hys225 Advance Access Publication 9 January 2013 Maintenance Therapy with Intravesical Bacillus Calmette Guérin in Patients with Intermediate- or High-risk

More information

CUA guidelines on the management of non-muscle invasive bladder cancer

CUA guidelines on the management of non-muscle invasive bladder cancer Original cua guidelines research CUA guidelines on the management of non-muscle invasive bladder cancer Wassim Kassouf, MD, CM, FRCSC; * Samer L. Traboulsi, MD; * Girish S. Kulkarni, MD, FRCSC; Rodney

More information

Guidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer

Guidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer Guidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer West Midlands Clinical Networks and Clinical Senate Coversheet for Network Expert Advisory Group

More information

Evan J. Lipson, M.D.

Evan J. Lipson, M.D. Update on treatment for Merkel cell, cutaneous squamous cell and basal cell cancers Evan J. Lipson, M.D. The Johns Hopkins University School of Medicine Bloomberg~Kimmel Institute for Cancer Immunotherapy

More information

Checkpoint Inibitors for Bladder Cancer

Checkpoint Inibitors for Bladder Cancer Checkpoint Inibitors for Bladder Cancer Daniel P. Petrylak, MD Professor of Medicine and Urology Director, GU Translational Working Group Co Director, Signal Transduction Program Smilow Cancer Center,

More information

Immunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know

Immunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know Immunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know Jeffrey Weber, MD, PhD Laura and Isaac Perlmutter Cancer Center NYU Langone Medical Center New York, New York What Is the Current

More information

BACKGROUND. Many patients with invasive urothelial cell cancer are poor candidates

BACKGROUND. Many patients with invasive urothelial cell cancer are poor candidates 2181 Treatment Options for Muscle-invasive Urothelial Cancer for Patients Who Were Not Eligible for Cystectomy or Neoadjuvant Chemotherapy With Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Report

More information

Bladder Cancer Guidelines

Bladder Cancer Guidelines Bladder Cancer Guidelines Agreed by Urology CSG: October 2011 Review Date: September 2013 Bladder Cancer 1. Referral Guidelines The following patients should be considered as potentially having bladder

More information

Optimizing treatment for metastatic bladder cancer in chemotherapy-resistant urothelial carcinoma. Moran Gadot M.D SHEBA Medical Center ISRAEL

Optimizing treatment for metastatic bladder cancer in chemotherapy-resistant urothelial carcinoma. Moran Gadot M.D SHEBA Medical Center ISRAEL Optimizing treatment for metastatic bladder cancer in chemotherapy-resistant urothelial carcinoma Moran Gadot M.D SHEBA Medical Center ISRAEL Disclosures none All (eligible) patients should get chemotherapy

More information

MANAGING PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER: OLD DISEASE, NEW IDEAS

MANAGING PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER: OLD DISEASE, NEW IDEAS MANAGING PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER: OLD DISEASE, NEW IDEAS This symposium took place on 12 th March 2016 as part of the European Association of Urology Congress 2016 in Munich, Germany

More information

Prostate cancer Management of metastatic castration sensitive cancer

Prostate cancer Management of metastatic castration sensitive cancer 18 th Annual Advances in Oncology - 2017 Prostate cancer Management of metastatic castration sensitive cancer Urothelial carcinoma Non-muscle invasive urothelial carcinoma Updates in metastatic urothelial

More information

Open clinical uro-oncology trials in Canada

Open clinical uro-oncology trials in Canada CLINICAL TRIALS Open clinical uro-oncology trials in Canada Eric Winquist, MD, Mary J. Mackenzie, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada ADRENOCORTICAL MALIGNANCIES

More information

Mixed low and high grade non muscle invasive bladder cancer: a histological subtype with favorable outcome

Mixed low and high grade non muscle invasive bladder cancer: a histological subtype with favorable outcome DOI 10.1007/s00345-014-1383-5 Original Article Mixed low and high grade non muscle invasive bladder cancer: a histological subtype with favorable outcome Tina Schubert Matthew R. Danzig Srinath Kotamarti

More information

Open clinical uro-oncology trials in Canada

Open clinical uro-oncology trials in Canada Open clinical uro-oncology trials in Canada Eric Winquist, MD, Mary J. Mackenzie, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada ADRENOCORTICAL MALIGNANCIES CISPLATIN-BASED

More information

Management of Difficult Cases of Non-Muscle Invasive Bladder Cancer

Management of Difficult Cases of Non-Muscle Invasive Bladder Cancer Management of Difficult Cases of Non-Muscle Invasive Bladder Cancer 1 Bladder Cancer Recurrence is common Progression is uncommon Progression is more important than recurrence There are indicators of recurrence

More information

Debate: Whole pelvic RT for high risk prostate cancer??

Debate: Whole pelvic RT for high risk prostate cancer?? Debate: Whole pelvic RT for high risk prostate cancer?? WPRT well, at least it ll get the job done.or will it? Andrew K. Lee, MD, MPH Associate Professor Department of Radiation Oncology Using T-stage,

More information

Immunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System

Immunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,

More information

NMIBC. Piotr Jarzemski. Department of Urology Jan Biziel University Hospital Bydgoszcz, Poland

NMIBC. Piotr Jarzemski. Department of Urology Jan Biziel University Hospital Bydgoszcz, Poland NMIBC Piotr Jarzemski Department of Urology Jan Biziel University Hospital Bydgoszcz, Poland 71 year old male patient was admitted to the Department of Urology First TURBT - 2 months prior to the hospitalisation.

More information

INMUNOTERAPIA I. Dra. Virginia Calvo

INMUNOTERAPIA I. Dra. Virginia Calvo INMUNOTERAPIA I Dra. Virginia Calvo LBA62. Health-related quality of life (HRQoL) for Pembrolizumab or placebo plus Carboplatin and Paclitaxel or nab-paclitaxel in patients with metastatic squamous NSCLC:

More information

Immunotherapy, an exciting era!!

Immunotherapy, an exciting era!! Immunotherapy, an exciting era!! Yousef Zakharia MD University of Iowa and Holden Comprehensive Cancer Center Alliance Meeting, Chicago November 2016 Presentation Objectives l General approach to immunotherapy

More information

Arieh L. Shalhav Is There a Risk in Robotic Nephroureterectomy?

Arieh L. Shalhav Is There a Risk in Robotic Nephroureterectomy? Arieh L. Shalhav Is There a Risk in Robotic Nephroureterectomy? 80 patients LNU (n = 40) or ONU (n = 40) CSS (p = 0.2), BRFS (p = 0.86), MFS (p = 0.12) similar for the entire cohort Subgroups of pt3 UTUC

More information

european urology 52 (2007)

european urology 52 (2007) european urology 52 (2007) 1123 1130 available at www.sciencedirect.com journal homepage: www.europeanurology.com Urothelial Cancer Long-Term Intravesical Adjuvant Chemotherapy Further Reduces Recurrence

More information

Radical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease

Radical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease Radical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease Disclosures I do not have anything to disclose Sexual function causes moderate to severe distress 2 years after

More information

Research Article Partial Cystectomy after Neoadjuvant Chemotherapy: Memorial Sloan Kettering Cancer Center Contemporary Experience

Research Article Partial Cystectomy after Neoadjuvant Chemotherapy: Memorial Sloan Kettering Cancer Center Contemporary Experience International Scholarly Research Notices, Article ID 702653, 6 pages http://dx.doi.org/10.1155/2014/702653 Research Article Partial Cystectomy after Neoadjuvant Chemotherapy: Memorial Sloan Kettering Cancer

More information